Early application of subretinal bevacizumab and tPA promising in eliminating subretinal haemorrhage
Accumulation of blood between the neurosensory retina and the retinal pigment epithelium (RPE), known as submacular haemorrhages (SMH), is a significant cause of sudden vision loss. In particular, if the SMH related to CNVM in neovascular age-related macular degeneration (AMD) is large and very thick, the prognosis is poor if left untreated or delayed in treatment. Surgical removal of the SMH through small or large retinal incisions, macular translocation, and RPE choroid grafts are the treatment methods used in the long-standing SMH.
A recent study published in BEYOGLU EYE JOURNAL has concluded that administering subretinal bevacizumab and subretinal tissue plasminogen activator (tPA) effectively removes subretinal hemorrhage under the fovea. It is necessary to continue intravitreal anti-VEGF treatment, as choroidal neovascular membrane activity continues after surgery.
The patients underwent pars plana vitrectomy (PPV) with simultaneous subretinal tPA and subretinal bevacizumab with 18% SF6 tamponade. Researchers evaluated the Anatomical and functional results of the patients before surgery and at the 1st, 6th, and 12th months after surgery, additional treatments, and complications following PPV.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.